With this milestone Ambu is cleared to address the +15 million annual procedure market for colonoscopy in the US.
Ambu already operates in the field of single-use endoscopy for pulmonary (visualisation of the airways) with aScope, a ~5m annual procedure market, and has sold more than 700,000 aScopes since the launch in 2013.
'We are very pleased with the approval by the FDA, which we see as a clear signal that there is a need for mitigating the risks of cross contamination within endoscopy, a risk that was recently ranked as the 2nd most critical health hazard in ECRI's report for 2018. The FDA approval marks a positive upgrade of our business potential,' says Lars Marcher, CEO of Ambu.
Contact and further information
Lars Marcher, President & CEO - Phone +45 5136 2490 . E-mail: lm@ambu.com
